Class information for:
Level 1: C ERBB 2//HER 2 NEU//P185

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
1882 2371 42.2 87%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
451 15419 HER 2//TRASTUZUMAB//LAPATINIB

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 C ERBB 2 Author keyword 58 29% 7% 165
2 HER 2 NEU Author keyword 25 17% 5% 130
3 P185 Author keyword 20 66% 1% 19
4 NEU Author keyword 20 31% 2% 54
5 HEREGULIN Author keyword 16 29% 2% 48
6 ERBB 2 Author keyword 14 22% 2% 56
7 SERUM HER 2 NEU Author keyword 13 80% 0% 8
8 C ERBB 3 Author keyword 11 56% 1% 14
9 ONCOGENE SCI Address 11 78% 0% 7
10 SERUM HER2 Author keyword 11 78% 0% 7

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 C ERBB 2 58 29% 7% 165 Search C+ERBB+2 Search C+ERBB+2
2 HER 2 NEU 25 17% 5% 130 Search HER+2+NEU Search HER+2+NEU
3 P185 20 66% 1% 19 Search P185 Search P185
4 NEU 20 31% 2% 54 Search NEU Search NEU
5 HEREGULIN 16 29% 2% 48 Search HEREGULIN Search HEREGULIN
6 ERBB 2 14 22% 2% 56 Search ERBB+2 Search ERBB+2
7 SERUM HER 2 NEU 13 80% 0% 8 Search SERUM+HER+2+NEU Search SERUM+HER+2+NEU
8 C ERBB 3 11 56% 1% 14 Search C+ERBB+3 Search C+ERBB+3
9 SERUM HER2 11 78% 0% 7 Search SERUM+HER2 Search SERUM+HER2
10 HER2 ECD 10 73% 0% 8 Search HER2+ECD Search HER2+ECD

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 NEU ONCOGENE 244 36% 23% 540
2 HER 2 NEU ONCOGENE 77 48% 5% 119
3 C ERBB 2 ONCOGENE 53 53% 3% 70
4 NEU DIFFERENTIATION FACTOR 51 33% 5% 126
5 HER 2 NEU 41 19% 8% 193
6 ERBB 2 PROTEIN 32 80% 1% 20
7 ERBB RELATED GENE 32 68% 1% 28
8 NEU ONCOGENE PROTEIN 32 88% 1% 15
9 C ERBB 2 32 19% 6% 148
10 NEU ONCOGENE PRODUCT 31 82% 1% 18

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
The ErbB signaling network: receptor heterodimerization in development and cancer 2000 1400 121 34%
THE BIOLOGY OF ERBB-2 NEU HER-2 AND ITS ROLE IN CANCER 1994 756 242 71%
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis 2007 201 210 34%
The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy 1998 423 104 69%
Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls 2011 21 71 56%
Specificity within the EGF family ErbB receptor family signaling network 1998 568 79 51%
ERBB2 oncogene in human breast cancer and its clinical significance 1998 319 177 73%
Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer 2003 95 90 76%
Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer 2006 66 64 58%
Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients 2009 37 105 58%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 ONCOGENE SCI 11 78% 0.3% 7
2 BREAST CANC BASIC PROGRAM 5 50% 0.3% 7
3 RECEPTOR BIOL CELL GROWTH 2 67% 0.1% 2
4 WERPUNKT ONKOL HAMATOL 2 29% 0.2% 5
5 CANC WIA 1 100% 0.1% 2
6 BREAST CANC BIOL 1 40% 0.1% 2
7 ONCOBIOL 1 13% 0.3% 7
8 CLIN SPECIAL GYNAECOL 1 33% 0.1% 2
9 CYTOL HISTOPATHOL 1 33% 0.1% 2
10 AGO STUDY GRP 1 50% 0.0% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000245938 HER3//NUCLEAR EGFR//EGFR FAMILY
2 0.0000235548 HER 2//HER2 TESTING//POLYSOMY 17
3 0.0000182526 BREAST CARCINOMA CELL LINE//BIOTINYLATED EPIDERMAL GROWTH FACTOR//BREAST CANCER BIOPSIES
4 0.0000179753 TRASTUZUMAB//LAPATINIB//PERTUZUMAB
5 0.0000163960 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2//ADVANCED METASTATIC DISEASE//ANTI EGF RECEPTOR ANTIBODY
6 0.0000144683 CANC VACCINE DEV PROGRAM//CANC SECT//ONCOANTIGENS
7 0.0000137156 EBP1//RADIOBIOL CANC//PA2G4
8 0.0000100984 IMMUNOGENE//MED MOLEC BIOL SHINJUKU KU//ERBB PROTEINS
9 0.0000067048 NIMOTUZUMAB//H R3//CETUXIMAB
10 0.0000062900 OVARIAN CARCINOMAS//CANC MONTREAL//6Q27